ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

Blinatumomab in First-Line ALL - Safety, Efficacy, and Experience

Salman Fazal

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai

Frontline Treatment of ALL: Current Standards and Emergence of CAR-T

University of Colorado Cancer Center

M. Schwartz

Clinically-Relevant Updates in ALL in Adults

Insights from 2023 ASH Annual Meeting

R. Cassaday

Immunotherapy and Sequencing CD19-Targeted Therapies in Adults With …

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

Summary of Recent Advances in Adult ALL

Yale Cancer Center

L. Mendez

Current Approaches in the Frontline Treatment of Adult ALL

Louisville Hematology Highlights

N. Short

Case-Based Insights on Managing Adults With R/R ALL

University of Colorado Division of Hematology

M. Schwartz

Transplantation in Adult ALL: Current Guidelines and Key Considerati…

ecancer

S. Tulpule

Cellular Therapy Strategies for Persistent Disease After Induction f…

Rush University Medical Center

V. Pullarkat

Management of Persistently MRD+ ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Odabasi Giden

Updated Results from the BLAST and TOWER Studies: Safety and Efficac…

Michael Burke

Next Questions in ALL

SOHO 2023 Eleventh Annual Meeting

E. Jabbour